# $BEFFJEZOS Social Sentiment & Intelligence — 2026-08-15 23:10 UTC

> **Asset:** $BEFFJEZOS  
> **Momentum Status:** Fading Quickly  
> **Timestamp:** 2026-08-15 23:10 UTC (2026-08-15T23:10:00Z)  
> **Canonical URL:** https://cryptitalk.com/2026-08-15-23-10/crypto/BEFFJEZOS  
> **Overview Brief:** https://cryptitalk.com/2026-08-15-23-10/crypto.md  

---

## 10-Minute Social Metrics
- **Posts Analyzed:** 1
- **Total Impressions:** 6.9K
- **Likes:** 149
- **Retweets:** 2
- **Comments:** 10

---


## Momentum & Sentiment Analysis
Total Engagement - Comments: 10, Retweets: 2, Likes: 149, Impressions: 6902


---

## Cited Community Posts & Evidence


### Post #1 by @jinseongeo83473
> **Author:** [@jinseongeo83473](https://x.com/jinseongeo83473)  
> **Metrics:** 8 likes · 0 retweets · 0 comments · 2.0K views  


> **Source Link:** [https://x.com/jinseongeo83473/status/2088746496636362793](https://x.com/jinseongeo83473/status/2088746496636362793)  


> **Visual Context:** The image is a table titled "Probability of Success² by Clinical Trial Phase and Therapeutic Area," showing transition success rates from P1 to P2, P2 to P3, and P3 to Approval, along with overall success rates across various therapeutic areas such as Oncology (3.4%), Metabolic/Endocrinology (19.6%), and Ophthalmology (32.6%), sourced from a 2019 study by Chi Heem Wong, Kien Wei Siah, and Andrew W. Lo published in *Biostatistics*. The 51.6% figure referenced in the post corresponds to the P3 to Approval success rate in the Metabolic/Endocrinology category, which the post clarifies represents only one phase transition rather than an overall clinical trial success rate.  

> 
> "$ABCL 
 ABCL635 Success Probability 51.6%? — The numbers are correct, but the interpretation is different.

The source of the attached table is
a clinical success rate study published by Wong·Siah·Lo in Biostatistics.

The actual paper has been verified. 

The study calculated"




---


## Contributing Accounts

- `@beffjezos` (https://x.com/beffjezos)